Cingulate Inc. shares surged 30.7% amid strong investor interest in its ADHD treatment technology. Trading volume was high, with 3.297 million shares traded, reflecting growing market attention. Don’t ...

Cingulate, Inc. (NASDAQ:CING) reported third quarter 2025 results on November 13 th, 2025. No revenues were recorded and operating expense totaled $6.0 million. The new drug application (NDA) to the ...

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with ...

Cingulate, Inc. (NASDAQ:CING) reported 2024 results on March 26 th, 2025. No revenues were recorded and operating expense of $15.6 million was recognized. Over the last several months, Cingulate has ...

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

S&P 500 and Nasdaq futures traded higher after the Dow Jones Industrial Average recorded its first close above 50,000. ・Asian markets looked set to open higher, with Japan’s Nikkei jumping more than 4 ...

This post has not been edited by the GamesBeat staff. Opinions by GamesBeat community writers do not necessarily reflect those of the staff. It’s been almost four years since Cing went out of business ...